用于检测膀胱癌的尿液检测方法。
Urine-based assays for the detection of bladder cancer.
作者信息
Villicana Patrick, Whiting Bryant, Goodison Steve, Rosser Charles J
机构信息
Department of Urology, The University of Florida, College of Medicine, Suite N2-3, PO Box 100247, Gainesville, FL 32610, USA.
出版信息
Biomark Med. 2009 Jun 1;3(3):265. doi: 10.2217/bmm.09.23.
Abstract
Bladder cancer is one of the most prevalent cancers worldwide. Furthermore, nonmuscle invasive bladder cancer has a 70% rate of recurrence, making it a considerable strain to the healthcare system. Patients with bladder cancer require repeat cystoscopic examinations of the bladder to monitor for tumor recurrence. The reason these patients have to undergo these costly, painful, invasive procedures is owing to the absence of accurate urine-based assays to detect the presence of bladder cancer noninvasively. Consequently, the development of a urine-based test to detect bladder cancer would be of tremendous benefit to both patients and healthcare systems. This article reports some of the more prominent urine markers in use today. In addition, the article will highlight some new technologies that are used to investigate novel urinary markers.
摘要
膀胱癌是全球最常见的癌症之一。此外，非肌层浸润性膀胱癌的复发率为70%，给医疗系统带来了相当大的压力。膀胱癌患者需要定期进行膀胱镜检查以监测肿瘤复发。这些患者不得不接受这些昂贵、痛苦且有创的检查，原因是缺乏准确的基于尿液的检测方法来无创检测膀胱癌的存在。因此，开发一种基于尿液的膀胱癌检测方法将对患者和医疗系统都大有裨益。本文报道了目前一些较为突出的尿液标志物。此外，本文还将重点介绍用于研究新型尿液标志物的一些新技术。
相似文献
1
Urine-based assays for the detection of bladder cancer.用于检测膀胱癌的尿液检测方法。
Biomark Med. 2009 Jun 1;3(3):265. doi: 10.2217/bmm.09.23.
2
Republished: non-invasive urine based tests for the detection of bladder cancer.再版：基于尿液的非侵入性膀胱癌检测方法。
Postgrad Med J. 2013 Jun;89(1052):352-7. doi: 10.1136/postgradmedj-2012-200812rep.
3
Non-invasive urine based tests for the detection of bladder cancer.基于尿液的无创检测膀胱癌。
J Clin Pathol. 2012 Nov;65(11):970-5. doi: 10.1136/jclinpath-2012-200812. Epub 2012 Jun 9.
4
Urinary biomarkers of bladder cancer: an update and future perspectives.膀胱癌的尿液生物标志物：最新进展与未来展望。
Biomark Med. 2013 Oct;7(5):779-90. doi: 10.2217/bmm.13.73.
6
[Bladder cancer biomarkers].[膀胱癌生物标志物]
Przegl Lek. 2010;67(7):479-83.
7
The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.经尿道膀胱肿瘤切除术在非肌层浸润性膀胱癌治疗中的重要性：新技术的系统评价
J Urol. 2014 Jun;191(6):1655-64. doi: 10.1016/j.juro.2014.01.087. Epub 2014 Feb 8.
8
[Present Situation and Prospect of Urinary Biomarkers For Bladder Cancer].[膀胱癌尿液生物标志物的现状与展望]
Sheng Li Ke Xue Jin Zhan. 2015 Aug;46(4):255-8.
9
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.在一项大型前瞻性多中心研究中，FGFR3、TERT和OTX1作为膀胱癌患者监测的尿液生物标志物组合
J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.
10
Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy.“替换膀胱镜检查”临床试验方案：用尿液检测取代侵入性膀胱镜检查用于非肌层浸润性膀胱癌监测——一项多中心、随机、2期医疗服务试验，比较使用Xpert膀胱癌监测仪或膀胱上皮细胞检测尿液检测与频繁膀胱镜检查进行癌症监测期间的生活质量。
Eur Urol Open Sci. 2024 Mar 21;63:19-30. doi: 10.1016/j.euros.2024.02.018. eCollection 2024 May.
引用本文的文献
1
Urinary Markers for Bladder Cancer Diagnosis and Monitoring.用于膀胱癌诊断和监测的尿液标志物
Front Cell Dev Biol. 2022 May 2;10:892067. doi: 10.3389/fcell.2022.892067. eCollection 2022.
2
Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies.通过微流控免疫分析对膀胱癌尿路上皮脱落细胞进行表型分析：唾液酸化-Tn作为液体活检中的新型生物标志物
Front Oncol. 2020 Sep 16;10:1774. doi: 10.3389/fonc.2020.01774. eCollection 2020.
3
Unbiased enrichment of urine exfoliated cells on nanostructured substrates for sensitive detection of urothelial tumor cells.基于纳米结构基底的尿液脱落细胞无偏富集用于尿路上皮肿瘤细胞的灵敏检测
Cancer Med. 2020 Jan;9(1):290-301. doi: 10.1002/cam4.2655. Epub 2019 Nov 10.
4
Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens.在临床尿液样本中对膀胱癌相关组织蛋白生物标志物候选物进行系统验证。
Oncotarget. 2018 Jul 20;9(56):30731-30747. doi: 10.18632/oncotarget.24578.
5
Bladder Cancer Academy 2018 Selected Summaries.2018年膀胱癌学会精选摘要
Rev Urol. 2018;20(1):31-37. doi: 10.3909/riu02001BCA.
6
Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles.微小RNA作为膀胱癌新型生物标志物的诊断意义：十篇文章的荟萃分析
World J Surg Oncol. 2017 Aug 3;15(1):147. doi: 10.1186/s12957-017-1201-9.
7
The expression of AEG-1 and Cyclin D1 in human bladder urothelial carcinoma and their clinicopathological significance.AEG-1和细胞周期蛋白D1在人膀胱尿路上皮癌中的表达及其临床病理意义。
Int J Clin Exp Med. 2015 Nov 15;8(11):21222-8. eCollection 2015.
8
New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer.非肌层浸润性尿路上皮癌新的及当代预后标志物
Korean J Urol. 2015 Aug;56(8):553-64. doi: 10.4111/kju.2015.56.8.553. Epub 2015 Jul 31.
9
Interaction network analysis of differentially expressed genes and screening of cancer marker in the urine of patients with invasive bladder cancer.浸润性膀胱癌患者尿液中差异表达基因的相互作用网络分析及癌症标志物筛选
Int J Clin Exp Med. 2015 Mar 15;8(3):3619-28. eCollection 2015.
10
Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer.Elf5的表观遗传调控与尿路上皮癌的上皮-间质转化相关。
PLoS One. 2015 Jan 28;10(1):e0117510. doi: 10.1371/journal.pone.0117510. eCollection 2015.
本文引用的文献
1
A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.一种多色荧光原位杂交检测可预测接受膀胱内治疗的高危浅表性膀胱肿瘤患者的复发情况。
BJU Int. 2009 Aug;104(3):336-9. doi: 10.1111/j.1464-410X.2009.08375.x. Epub 2009 Feb 10.
2
Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia.通过对脱落尿路上皮进行分析鉴定出的膀胱癌相关基因表达特征。
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):444-53. doi: 10.1158/1055-9965.EPI-08-1002. Epub 2009 Feb 3.
3
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
4
Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.通过二维液相色谱与质谱联用鉴定的人转移模型中核糖体蛋白的差异表达。
Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):329-39.
5
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.非肌层浸润性膀胱癌（Ta、T1和Tis期）管理指南：2007年更新版
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
6
Voided urinary cytology in bladder cancer: is it time to review the indications?膀胱癌的尿脱落细胞学检查：是时候重新审视其适应证了吗？
Urology. 2007 Aug;70(2):267-71. doi: 10.1016/j.urology.2007.03.070.
7
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.基因表达特征可预测非肌层浸润性膀胱癌的预后：一项多中心验证研究。
Clin Cancer Res. 2007 Jun 15;13(12):3545-51. doi: 10.1158/1078-0432.CCR-06-2940.
8
Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling.尿蛋白质组分析揭示的膀胱癌相关糖蛋白特征
J Proteome Res. 2007 Jul;6(7):2631-9. doi: 10.1021/pr0700807. Epub 2007 May 23.
9
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.使用5-氨基乙酰丙酸诱导荧光诊断对浅表性膀胱癌复发风险进行临床相关降低：前瞻性随机研究的8年结果
Urology. 2007 Apr;69(4):675-9. doi: 10.1016/j.urology.2006.12.023.
10
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.使用尿液生物标志物进行膀胱癌监测：患者视角
J Urol. 2007 Apr;177(4):1277-82; discussion 1282. doi: 10.1016/j.juro.2006.11.066.
Zotero 插件